2023
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
Wang Z, Muthusamy V, Petrylak D, Anderson K. Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy. Npj Precision Oncology 2023, 7: 70. PMID: 37479885, PMCID: PMC10362036, DOI: 10.1038/s41698-023-00417-5.Peer-Reviewed Original ResearchBladder cancerBC cellsEarly phase clinical trialsPhase clinical trialsDurable responsesMetastatic diseaseMost patientsFGFR3 alterationsPrevalent malignancyClinical trialsFGFR3 fusionsPreclinical studiesFGFR inhibitorsHDAC inhibitorsFGFR3 expressionEfficient therapyTherapyCancerQuisinostatFGFR3New mechanistic insightsInhibitorsCellsPatientsMalignancy
2016
Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor
Rullo A, Fitzgerald K, Muthusamy V, Liu M, Yuan C, Huang M, Kim M, Cho A, Spiegel D. Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie 2016, 128: 3706-3710. DOI: 10.1002/ange.201510866.Peer-Reviewed Original ResearchAntibody-recruiting small moleculeUrokinase-type plasminogen activator receptorMetastatic cancerPlasminogen activator receptorAntibody-recruiting moleculesCancer cell surface markersCell surface markersImmune responseNon-peptide ligandsTumor growthActivator receptorWeight lossCancer cellsCancerAgent doxorubicinUrokinase receptorReceptorsImmunotherapeuticsSmall moleculesSelective strategy